Clinical Trial Update: A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. [Phase 3]

View source ↗

Summary

Phase III randomized study assessing intercalating chemotherapy with gefitinib versus chemotherapy alone as adjuvant treatment in completely resected NSCLC with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Yonsei University | Conditions: Completely Resected NSCLC With Common EGFR Mutations | Phase 3 | Status: UNKNOWN